Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus

NCT01408576 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1250

Enrollment

INDUSTRY

Sponsor class

Conditions

Systemic Lupus Erythematosus

Interventions

DRUG: Epratuzumab
DRUG: Epratuzumab

Sponsor

UCB Pharma